Okay, let's tackle this question. The question is about the only thrombolytic agent approved for acute ischemic stroke. First, I need to recall which thrombolytics are used in stroke. I remember that alteplase is the one commonly mentioned. But wait, other agents like streptokinase or urokinase are used in other conditions, like myocardial infarction.

So the core concept here is the specific approval for stroke. Alteplase, also known as tPA (tissue plasminogen activator), is a recombinant enzyme that converts plasminogen to plasmin, which breaks down fibrin in blood clots. The FDA approved alteplase for acute ischemic stroke within 3-4.5 hours of symptom onset. Other thrombolytics might have different indications, like streptokinase for DVT or MI but not stroke.

Now, the wrong options: Let's say the options include streptokinase, urokinase, and something else. Streptokinase is a bacterial protein that works by binding to plasminogen, but it's not approved for stroke because of higher risk of hemorrhage. Urokinase is another fibrinolytic, but again, not approved for stroke. Maybe there's a newer drug like tenecteplase, but that's also not approved for stroke.

The clinical pearl here is that alteplase is the only FDA-approved thrombolytic for acute ischemic stroke, and timing is critical—within 3-4.5 hours. Students should remember this because other agents are contraindicated or not approved for this use. Also, the risk of intracranial hemorrhage is a major concern, so strict criteria must be followed.

**Core Concept**
Acute ischemic stroke requires rapid thrombolysis to restore cerebral perfusion. **Alteplase (tPA)** is the only FDA-approved thrombolytic for this indication, acting via plasminogen activation to dissolve fibrin clots within 3-4.5 hours of symptom onset. Other agents lack approval due to safety concerns or efficacy data in stroke.

**Why the Correct Answer is Right**
**Alteplase** is a recombinant tissue plasminogen activator (tPA) that specifically targets fibrin in clots, minimizing systemic fibrinolysis. It is FDA-approved for acute ischemic stroke when administered within 3-4.5 hours of symptom onset. Its mechanism involves converting plasminogen to plasmin, which degrades fibrin, restoring blood flow while balancing the risk of hemorrhage.

**Why Each Wrong Option is Incorrect**
**Option A:** **Streptokinase** is a bacterial protein that activates plasminogen nonspecifically, increasing risk of intracranial hemorrhage in stroke. **Option B:** **Urokinase** lacks FDA approval for stroke due to insufficient efficacy and safety data. **Option C:** **Tenecteplase** is a third-generation tPA but is not approved for acute stroke; it’s used in ST-segment elevation myocardial infarction (STEMI) instead.

**Clinical Pearl / High-Yield Fact**
Never use streptokinase or urokinase for acute ischemic stroke—only **altepl

✓ Correct Answer: A. Tissue Plasminogen activator